Investigational Drug Information for Solithromycin
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Solithromycin?
Solithromycin is an investigational drug.
There have been 11 clinical trials for Solithromycin.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2013.
The most common disease conditions in clinical trials are Pneumonia, Bacterial, Pneumonia, and Gonorrhea. The leading clinical trial sponsors are Cempra Inc, Melinta Therapeutics, Inc., and Department of Health and Human Services.
There are one hundred and eleven US patents protecting this investigational drug and nine hundred and forty-seven international patents.
Summary for Solithromycin
| US Patents | 111 |
| International Patents | 947 |
| US Patent Applications | 330 |
| WIPO Patent Applications | 289 |
| Japanese Patent Applications | 69 |
| Clinical Trial Progress | Phase 3 (2013-11-01) |
| Vendors | 25 |
Recent Clinical Trials for Solithromycin
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia | Biomedical Advanced Research and Development Authority | Phase 2/Phase 3 |
| Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia | Cempra Inc | Phase 2/Phase 3 |
| Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia | Melinta Therapeutics, Inc. | Phase 2/Phase 3 |
Clinical Trial Summary for Solithromycin
Top disease conditions for Solithromycin
Top clinical trial sponsors for Solithromycin
US Patents for Solithromycin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Solithromycin | See Plans and Pricing | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | See Plans and Pricing |
| Solithromycin | See Plans and Pricing | Hamamelitannin analogues and uses thereof | UNIVERSITEIT GENT (Ghent, BE) | See Plans and Pricing |
| Solithromycin | See Plans and Pricing | Pharmaceutical composition for the treatment of multi-drug resistant infections | Council of Scientific & Industrial Research (New Delhi, IN) | See Plans and Pricing |
| Solithromycin | See Plans and Pricing | Treatments for resistant acne | VYOME BIOSCIENNCES PVT. LTD. (New Delhi, IN) | See Plans and Pricing |
| Solithromycin | See Plans and Pricing | Sulfur(VI) fluoride compounds and methods for the preparation thereof | The Scripps Research Institute (La Jolla, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Solithromycin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Solithromycin | Australia | AU2015339012 | 2034-10-31 | See Plans and Pricing |
| Solithromycin | Brazil | BR112017008945 | 2034-10-31 | See Plans and Pricing |
| Solithromycin | Canada | CA2966005 | 2034-10-31 | See Plans and Pricing |
| Solithromycin | European Patent Office | EP3212668 | 2034-10-31 | See Plans and Pricing |
| Solithromycin | Spain | ES2832711 | 2034-10-31 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
